Concepedia

William R. Schelman

WR

Statistics

Publications

40

Citations

2.1K

H-Index

22

Active since

1997

Affiliations

University of Wisconsin Carbone Cancer Center(Current)

University of Wisconsin–Madison

National Cancer Institute

The University of Texas MD Anderson Cancer Center

Eli Lilly (United States)

William R. Schelman is an author at University of Wisconsin Carbone Cancer Center specializing in oncology, medicine, and pharmacology.

Publications per year

1997–2025

40

Publications

40

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Shahneen Sandhu, William R. Schelman, George Wilding et al. · The Lancet Oncology · 2013 · 558 citations

, , +12

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero et al. · The Lancet · 2023 · 323 citations · Full text

, , +9

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Mitesh J. Borad, Shantan Reddy, Nathan Bahary et al. · Journal of Clinical Oncology · 2014 · 191 citations · Full text

, , +17

A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma

Tabraiz A Mohammed, Kyle D. Holen, Renata Jaskula‐Sztul et al. · The Oncologist · 2011 · 91 citations · Full text

, , +17

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

Vincent Chung, Elisabeth I. Heath, William R. Schelman et al. · Cancer Chemotherapy and Pharmacology · 2011 · 83 citations

, , +14

1–5 of 40